Last Thursday, March 14, Rezdiffra (resmetirom) became the first drug approved in the US for MASH. Five leading North American MASLD patient advocates join the Surfers to discuss their feelings about this approval along with the opportunities and challenges that lie ahead.
In continuing conversation around clinical care pathways and the complex of metabolic diseases, SurfingNASH explores the key relationship and interplay between endocrinology and hepatology. This conversation features Cyrielle Caussy alongside Surfers Jörn Schattenberg, Louise Campbell and Roger Green discussing why endocrinology clinics are a critical setting for early identification of patients with NAFLD and NASH.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation the group shares recollections of their introductions to the podcast as we play throwback clips to their debut appearances.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the original ‘Big Band’ of Surfers Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green. In this conversation, Stephen shares his latest work and interests before the group listens and reacts to a clip of the original introduction featured on earlier episodes.
The Surfing NASH 3rd Anniversary Special offers a look back at the history of the podcast and the future of Fatty Liver with the Surfers and interviewees Amy Articolo, Donna Cryer and Frédéric Cren.
In this episode of the Rising Tide series for frontline professionals, the patients themselves and caregivers, co-hosts Ken Cusi and Roger Green are joined by KOL in hepatology, Manal Abdelmalek and KOL in endocrinology, Scott Isaacs for a deeper dive into Fatty Liver, NAFLD and NASH. The group discusses: morbidities and mortalities related to fatty liver disease, paradigm-shifting data, screening for risk stratification, pediatric and adolescent populations, unique key takeaways and much more.
The Surfers evaluate a draft report from the Institute for Clinical and Economic Review (ICER) on resmetirom and obeticholic acid for NASH. This high-caliber session offers a plethora of practical considerations around accessing approved NASH pharmacotherapies for those most in need.
Surfing the NASH Tsunami hosts its Season 3 finale to celebrate a momentous year in Fatty Liver through a series of interviews with Key Opinion Leaders. For this second installment, Surfers Louise Campbell and Roger Green are joined by Jeff Lazarus to discuss a “drugs-plus” approach to liver disease, interprofessional collaboration, guidelines and much more.
Executive Director Veronica Miller joins guest Manal Abdelmalek and co-host Jörn Schattenberg (both Steering Committee members) to introduce the origins of the Liver Forum. This conversation goes on to explore an ongoing project aimed to develop research tools and metrics that can capture the richness available in a plethora of data emerging from NASH studies.
In this episode discussing the Liver Forum, Jörn Schattenberg, Manal Abdelmalek, Veronica Miller and Roger Green investigate how to study efficacy and safety in real time, using collective knowledge and experience with therapies for advancing liver disease. Jörn, Manal and Veronica each provide their unique introductions to the steering committee and elaborate on the Forum’s efforts toward moving the field forward.
